Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Arch Acad Emerg Med ; 12(1): e19, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38371443

RESUMEN

Introduction: The specific impact on calcium dynamics after non-massive blood transfusions remains relatively unexplored. This study aimed to compare pre- and post-transfusion calcium levels in patients receiving blood and blood product in the emergency department. Methods: This is a single-center, prospective, cross-sectional study conducted at the Emergency Department of Gazi University Health Research and Application Center Hospital in Ankara, Turkey, from January 1, 2020, to August 31, 2020. The study included adult patients who underwent blood and blood product transfusions, and serum calcium levels were measured and compared from samples taken before and after transfusion. Results: A total of 292 participants were enrolled in the study, with 242 participants included in the final analysis. The mean total calcium level was 8.41 ± 0.76 mg/dL before transfusion and 8.34 ± 0.71 mg/dL after transfusion (p=0.012). When examining the corrected calcium values after receiving blood products based on the type of blood products, participants who received apheresis platelets had a post-transfusion corrected calcium value of 8.26 ±0.41 mg/dL, with a pre-transfusion value of 9.09 ±0.49 mg/dL (p<0.01). The post-transfusion ionized calcium value for participants receiving apheresis was 1.04 ±0.08 mg/dL, compared to 1.15 ±0.09 mg/dL for those who did not receive apheresis (p=0.049). There was a significant relationship between receiving fresh frozen plasma and post-transfusion ionized calcium values (p=0.024). Conclusion: This study demonstrated that transfusion-associated hypocalcemia can occur even at mild levels in patients receiving blood and blood product transfusions in the emergency department. However, it is suggested that the clinical effects of hypocalcemia, even when occurring based on the type and quantity of blood products, are minimal and negligible.

3.
J Pediatr Hematol Oncol ; 45(1): e119-e120, 2023 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-35380551

RESUMEN

Human Rhinovirus (HRV) is one of the most common pathogens causing acute respiratory tract infections in infants and children. Several reports suggest that HRV has the potential to cause chronic infection after an acute viral infection in an immunosuppressed patient. Although chronic HRV infection has been reported in lung transplant recipients, patients with hypogammaglobulinemia and cystic fibrosis, the duration and severity of HRV infection remain unclear. In this study, we present a case of persistent HRV infection in a stem cell transplanted leukemia patient. This report raises several questions regarding the risk factors, duration, and severity of persistent HRV infection in acute leukemia patients, which warrants prospective and longitudinal studies.


Asunto(s)
Infecciones por Enterovirus , Enterovirus , Leucemia , Infecciones por Picornaviridae , Infecciones del Sistema Respiratorio , Lactante , Humanos , Niño , Rhinovirus , Estudios Prospectivos , Infección Persistente , Infecciones por Picornaviridae/complicaciones , Infecciones del Sistema Respiratorio/etiología , Leucemia/complicaciones , Leucemia/terapia
8.
Blood Coagul Fibrinolysis ; 24(1): 102-5, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23103728

RESUMEN

In this article, we present a 7-year-old boy with Schoenlein-Henoch purpura (HSP) presented with compartment syndrome and factor XIII deficiency and treated with recombinant factor VIIa and fasciotomy. Treatment decisions for patients with HSP presenting with compartment syndrome should be made on a case-by-case basis. Factor XIII deficiency should be in mind in these patients. The use of recombinant factor VIIa might be effective and well tolerated for treating hemorrhage in patients with HSP and compartment syndrome. Surgical treatment should be preferred in patients with compartment syndrome. However, in patients who have a coagulation defect, the first priority is to correct the clotting deficiency. The use of recombinant factor VIIa is a treatment option for children who develop compartment syndrome due to a coagulation defect.


Asunto(s)
Síndromes Compartimentales/etiología , Descompresión Quirúrgica , Factor VIIa/uso terapéutico , Deficiencia del Factor XIII/etiología , Hemorragia/tratamiento farmacológico , Vasculitis por IgA/complicaciones , Cuidados Preoperatorios , Pruebas de Coagulación Sanguínea , Pérdida de Sangre Quirúrgica/prevención & control , Niño , Terapia Combinada , Síndromes Compartimentales/cirugía , Factor VIII/uso terapéutico , Factor XIII/metabolismo , Fasciotomía , Fibrinógeno/uso terapéutico , Traumatismos de la Mano/complicaciones , Hemorragia/etiología , Humanos , Vasculitis por IgA/sangre , Vasculitis por IgA/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Masculino , Metilprednisolona/uso terapéutico , Proteínas Recombinantes/uso terapéutico , Dispositivos de Acceso Vascular/efectos adversos
9.
Int J Endocrinol ; 2012: 156854, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22811708

RESUMEN

The aim of this study was to investigate the effects of thyroid hormone deficiencies in childhood on the elements of coagulation proteins. Consecutive 54 children with hypothyroidism and 55 healthy controls aged 1 month-16 years were enrolled. One year after Na-L-thyroxine treatment, the study parameters were reevaluated. Thyroid function tests, procoagulant and anticoagulant proteins were performed for children with hypothyroidism and healthy controls. Significant decreased results were found in children with hypothyroidism in terms of fibrinogen, TT, and anticoagulant proteins including AT, PC, PS, and fPS. Significant increases were found with respect to APTT, fibrinogen, and TT. In the evaluation of posttreatment changes a statistically significant increase was found in vWF, FVIII, AT, PC, PS, and fPS. A positive correlation was found between fT4 and vWF, FVIII, PC, and PS. We would like to emphasize that the coagulation system especially vWF and FVIII, and particularly the anticoagulant system, should be monitored closely in patients followed up for hypothyroidism. Thyroid hormones should be examined and, if necessary, hormone replacement therapy should be administered in patients followed up for a predisposition to coagulation. Additionally, further studies with larger series are needed to investigate the effects of hypothyroidism on the coagulation system.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...